Shares of Argos Therapeutics Inc (NASDAQ:ARGS) have been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $24.00.
Separately, ValuEngine upgraded shares of Argos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday.
Argos Therapeutics (NASDAQ ARGS) traded down $0.23 during mid-day trading on Friday, reaching $1.69. 475,066 shares of the company traded hands, compared to its average volume of 775,469. Argos Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $106.00. The firm has a market capitalization of $7.38, a price-to-earnings ratio of -0.07 and a beta of 0.99. The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of -1.46.
Argos Therapeutics (NASDAQ:ARGS) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.00) EPS for the quarter.
An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. purchased a new stake in Argos Therapeutics Inc (NASDAQ:ARGS) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics as of its most recent filing with the Securities and Exchange Commission.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.